Traders should monitor upcoming clinical data readouts in 2H26 for XmAb819 and XmAb541, which could serve as significant value inflection points. The strong cash position and extended runway reduce near-term dilution risk.
Price Chart
Executive Summary
Xencor reported financial results for Q4 and full year 2025, showing increased revenue and improved net loss compared to 2024, driven by collaboration and royalty income. The company highlighted clinical progress across its pipeline, including XmAb819 and XmAb541 in oncology and XmAb942 in inflammatory bowel disease, with key data expected in 2026. Xencor maintains a strong cash position and expects to end 2026 with $400–430 million in cash, sufficient to fund operations through 2028.
Key Financial Metrics
Key Facts
- Revenue increased 13.7% YoY to $125.6 million in 2025, driven by Alexion and Incyte license agreements.
- Net loss narrowed significantly to $91.9 million ($1.24 EPS) in 2025 vs. $232.6 million ($3.58 EPS) in 2024.
- Cash, cash equivalents, and marketable securities totaled $610.8 million as of December 31, 2025.
- Xencor expects to end 2026 with $400–430 million in cash and sufficient runway through 2028.
- Key clinical catalysts expected in 2H26, including dose-expansion data for XmAb819 and XmAb541, and initiation of a first-in-human study for XmAb412.
Financial Impact
Revenue increased by $15.1 million YoY to $125.6 million; net loss decreased by $140.7 million YoY to $91.9 million.
Risk Factors
- Clinical trial setbacks could delay or derail development timelines.
- Reliance on partnership revenue from Alexion and Incyte creates execution and dependency risk.
- Market volatility in biotech sector may impact stock performance despite strong fundamentals.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001326732-26-000014 |
| Document: xncr-20260225.htm | 0001326732-26-000014 |
| Document: 0001326732-26-000014-index-headers.html | 0001326732-26-000014 |
| Document: 0001326732-26-000014-index.html | 0001326732-26-000014 |
| Document: 0001326732-26-000014.txt | 0001326732-26-000014 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $20.00 $26.62 | ▲ +33.10% | ▲ +32.50% | $24.31 (+21.55%) |
Jun 17, 2026 15w ago | Insider Cluster | $12.64 $14.95 | ▲ +18.28% | ▲ +17.74% | $24.31 (+92.33%) |
Jun 15, 2026 15w ago | 144 | $12.21 $14.96 | ▲ +22.52% | ▲ +23.27% | $24.31 (+99.10%) |
Jun 15, 2026 15w ago | 144 | $12.21 $14.96 | ▲ +22.52% | ▲ +23.27% | $24.31 (+99.10%) |
May 6, 2026 21w ago | 8-K | $12.31 $11.42 | ▲ +7.23% | ▲ +10.37% | $24.31 (−97.48%) |
May 5, 2026 21w ago | 8-K | $12.85 $11.21 | ▼ −12.76% | ▼ −17.72% | $24.31 (+89.18%) |
Apr 27, 2026 22w ago | 8-K | $12.15 $11.63 | ▼ −4.28% | ▼ −9.75% | $24.31 (+100.08%) |
Mar 5, 2026 30w ago | Insider Cluster | $11.16 $12.81 | ▲ +14.78% | ▲ +18.57% | $24.31 (+117.83%) |
Mar 4, 2026 30w ago | 8-K | $11.16 $12.81 | ▼ −14.78% | ▼ −18.57% | $24.31 (−117.83%) |
Feb 25, 2026 31w ago | 8-K | $11.98 $12.40 | ▲ +3.51% | ▲ +8.74% | $24.31 (+102.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access